Competitive pressure from larger and specialized rivals
The company competes with firms such as Bio-Techne, 10x Genomics, Bruker, and others across multiple platforms.
- Scope
- proteomics, spatial biology, diagnostics
- Materiality
- high
Quanterix Corp
Quanterix Corp develops and commercializes ultra-sensitive life science instruments, assay kits, and related services used to measure proteins and biomarkers in biological samples. Its portfolio includes Simoa-based instruments, consumables, and the Accelerator Laboratory service platform, with customers served through direct sales and distribution channels in North America, Europe, and other international markets.
−85,3 %
46,8 %
−77,1 %
+1,1 %
2.84
2.11
| % | |
|---|---|
| Instruments | 20% Analytical instruments used for proteomics, biomarker detection, and spatial biology workflows. |
| Consumables and assay kits | 55% Reagents, bead-based consumables, and assay kits used with installed instruments. |
| Services | 25% Accelerator Laboratory and other research or collaboration services. |
Quanterix sells primarily to life science researchers, pharmaceutical and biotech companies, and clinical research...
- Pharmaceutical and biotech R&Dprimary
Buys instruments, consumables, and services for biomarker discovery and clinical research.
- Academic and government researchprimary
Uses Simoa systems and assays for basic and translational research applications.
- Clinical research organizationssecondary
Outsources specialized testing and laboratory services for sponsored studies.
- Diagnostic and clinical partnerssecondary
Evaluates assays and platforms for future diagnostic or LDT applications.
Quanterix operates with a global customer base, with a substantial share of revenue generated outside North America...
- •Revenue is materially international, with customers outside North America
- •Sales and support staff are concentrated in North America and Europe
- •China and APAC are targeted for broader distribution and support coverage
- •Manufacturing is split between in-house facilities and third-party partners
- •International sales depend on distributors, local compliance, and service coverage
Quanterix is focused on expanding its installed base, launching new instruments and tests, and extending its platform...
01
Commercialize new instruments and assaysshort-term
New products are central to replacing aging systems and sustaining platform relevance.
02
Expand diagnostics and clinical applicationsmedium-term
Diagnostic use cases can broaden the addressable market beyond research customers.
03
Build international distribution coveragemedium-term
International markets are a meaningful source of growth and require local support.
04
Strengthen customer retention and installed-base utilizationshort-term
Consumables and service revenue depend on active instrument usage and repeat demand.
Quanterix faces competition from larger life science instrument companies and smaller specialists across proteomics,...
Customer concentration
A meaningful portion of revenue comes from a limited number of large customers, increasing volatility if one reduces spend.
- Scope
- top customers and major pharma accounts
- Materiality
- high
Product development and launch delays
Technical challenges or supply chain issues could slow commercialization of next-generation instruments.
- Scope
- instrument refresh and new assays
- Materiality
- high
Acquisition integration and internal control risk
Integrating acquired businesses and remediating control weaknesses can create reporting and execution risk.
- Scope
- Akoya integration and financial reporting
- Materiality
- high
International execution and compliance risk
Growth outside North America depends on distributors, foreign regulations, and anti-bribery compliance.
- Scope
- Europe, China, APAC
- Materiality
- medium
Revenue recognition across multiple revenue streams
Quarterly mix and timing can shift reported revenue materially
Acquisition accounting for Akoya and other deals
Can affect revenue, amortization, and impairment risk
Goodwill and intangible asset impairment
Potential non-cash charges if expected benefits do not materialize
Contingent consideration and fair value estimates
Can create earnings volatility through remeasurement
: 29.4.2026